Why does CRT work better in women?
| العنوان: | Why does CRT work better in women? |
|---|---|
| المؤلفون: | A Lorente Ros, J M Monteagudo, V Calvi, M J Sancho-Tello, A H Maass, L Van Erven, S Ellery, M Nurnberg, G Voros, K Vernooy, A Quesada, J G Martinez, E Nof, J M Tolosana, J L Zamorano Gomez |
| المصدر: | European Heart Journal. 43 |
| بيانات النشر: | Oxford University Press (OUP), 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Cardiology and Cardiovascular Medicine |
| الوصف: | Introduction It has been recently postulated that cardiac resynchronization therapy (CRT) might have a higher efficacy in women, with a greater reverse cardiac remodeling in this population. The reasons for these differences are not yet completely understood. We aimed to detect sex differences in the degree of ventricular asynchrony (VA) and mitral regurgitation (MR) in patients undergoing CRT implantation. Methods We analyzed baseline characteristics of a prospective international clinical trial that compared CRT response rate in a HF population with a comparable distribution of men and women (BIOWOMEN). A total of 408 patients were analyzed. The degree of mitral regurgitation and intra and inter-ventricular asynchrony was assessed by independent echocardiographers in a core lab. Inter-ventricular asynchrony was defined as an interventricular mechanical delay greater than 40ms and intra-ventricular asynchrony as differences greater than 50ms among regional pre-ejection periods. Multivariable logistic regression was performed using commercial data analysis software. Results As expected, ventricular asynchrony was dependent on QRS duration and the presence of LBBB (p Conclusions In our analysis, for a given QRS duration there was not a higher degree of asynchrony in women with HF. However, female sex was associated with a significantly higher proportion of mitral regurgitation for a given QRS duration irrespective of baseline HF etiology. Further investigations are needed to establish a possible link between these findings and better CRT outcomes in women. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): BIOTRONIK SE & Co. KG |
| تدمد: | 1522-9645 0195-668X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::b8a531b9178aeee199d28e79411be57e https://doi.org/10.1093/eurheartj/ehac544.2498 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi...........b8a531b9178aeee199d28e79411be57e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15229645 0195668X |
|---|